Increased intestinal permeability, measured by serum zonulin, is associated with metabolic risk markers in overweight pregnant women

Metabolism: Clinical and Experimental

Volumn 69, Issue , 2017, Pages 43-50

  Mokkala, Kati ^a   Pellonperä, Outi ^b   Röytiö, Henna ^a   Pussinen, Pirkko ^c   Rönnemaa, Tapani ^a   Laitinen, Kirsi ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Intestinal permeability; Low grade inflammation; Metabolic endotoxemia; Overweight; Pregnancy

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVE C REACTIVE PROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZONULIN; BIOLOGICAL MARKER; CHOLERA TOXIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIET RESTRICTION; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE MUCOSA PERMEABILITY; LIPID METABOLISM; MAJOR CLINICAL STUDY; OBESITY; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; FINLAND; INTESTINE; METABOLIC DISEASES; METABOLISM; OVERWEIGHT; PERMEABILITY; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT;

ADULT; BIOMARKERS; CHOLERA TOXIN; CROSS-SECTIONAL STUDIES; ENDOTOXEMIA; FEMALE; FINLAND; GLUCOSE; HUMANS; INFLAMMATION; INTESTINES; LIPID METABOLISM; METABOLIC DISEASES; OVERWEIGHT; PERMEABILITY; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT;

EID: 85011886993     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.12.015     Document Type: Article

References (50)

1. [1] Pantham, P., Aye, I.L., Powell, T.L., Inflammation in maternal obesity and gestational diabetes mellitus. Placenta 36 (2015), 709–715.
2. [2] Lain, K.Y., Catalano, P.M., Metabolic changes in pregnancy. Clin Obstet Gynecol 50 (2007), 938–948.
3. [3] Ingvorsen, C., Brix, S., Ozanne, S.E., Hellgren, L.I., The effect of maternal inflammation on foetal programming of metabolic disease. Acta Physiol (Oxf) 214 (2015), 440–449.
4. [4] Fox, C.S., Coady, S., Sorlie, P.D., Levy, D., Meigs, J.B., D'Agostino, R.B. Sr., et al. Trends in cardiovascular complications of diabetes. JAMA 292 (2004), 2495–2499.
5. [5] Calder, P.C., Ahluwalia, N., Brouns, F., Buetler, T., Clement, K., Cunningham, K., et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 106:Suppl. 3 (2011), S5–78.
6. [6] Santos, A.C., Lopes, C., Guimarães, J.T., Barros, H., Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes (Lond) 29 (2005), 1452–1456.
7. [7] Wang, X., Bao, W., Liu, J., Ouyang, Y.Y., Wang, D., Rong, S., et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 36 (2013), 166–175.
8. [8] Pfützner, A., Forst, T., High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 8 (2006), 28–36.
9. [9] Kac, G., Vaz, J.S., Schlüssel, M.M., Moura, A.S., C-reactive protein and hormones but not IL-6 are associated to body mass index in first trimester of pregnancy. Arch Gynecol Obstet 284 (2011), 567–573.
10. [10] Christian, L.M., Porter, K., Longitudinal changes in serum proinflammatory markers across pregnancy and postpartum: effects of maternal body mass index. Cytokine 70 (2014), 134–140.
11. [11] Friis, C.M., Paasche Roland, M.C., Godang, K., Ueland, T., Tanbo, T., Bollerslev, J., et al. Adiposity-related inflammation: effects of pregnancy. Obesity (Silver Spring) 21 (2013), E124–E130.
12. [12] Zak-Gołąb, A., Kocełak, P., Aptekorz, M., Zientara, M., Juszczyk, L., Martirosian, G., et al. Gut microbiota, microinflammation, metabolic profile, and zonulin concentration in obese and normal weight subjects. Int J Endocrinol, 674106, 2013, 10.1155/2013/674106 [Epub 2013 Jul 18].
13. [13] Moreno-Navarrete, J.M., Sabater, M., Ortega, R.W., Fernández-Real, J.M., Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS One, 7, 2012, e37160, 10.1371/journal.pone.0037160 [Epub 2012 May 18].
14. [14] Zhang, D., Zhang, L., Zheng, Y., Yue, F., Russell, R.D., Zeng, Y., Circulating zonulin levels in newly diagnosed Chinese type 2 diabetes patients. Diabetes Res Clin Pract 106 (2014), 312–318.
15. [15] Jayashree, B., Bibin, Y.S., Prabhu, D., Shanthirani, C.S., Gokulakrishnan, K., Lakshmi, B.S., et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem 388 (2014), 203–210.
16. [16] Moreira, A.P., Texeira, T.F., Ferreira, A.B., Peluzio Mdo, C., Alfenas, R.C., Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr 108 (2012), 801–809.
17. [17] Cani, P.D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A.M., Delzenne, N.M., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57 (2008), 1470–1481.
18. [18] Mokkala K, Röytiö H, Munukka E, Pietilä S, Ekblad U, Rönnemaa T, et al. Gut microbiota richness and composition and dietary intake of overweight pregnant women are related to serum zonulin concentration, a marker for intestinal permeability.
19. [19] Otvos, J.D., Shalaurova, I., Wolak-Dinsmore, J., Connelly, M.A., Mackey, R.H., Stein, J.H., et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem 61 (2015), 714–723.
20. [20] Sapone, A., de Magistris, L., Pietzak, M., Clemente, M.G., Tripathi, A., Cucca, F., et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 55 (2006), 1443–1449.
21. [21] Pacifico, L., Bonci, E., Marandola, L., Romaggioli, S., Bascetta, S., Chiesa, C., Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease. World J Gastroenterol 20 (2014), 17107–17114.
22. [22] Zhang, D., Zhang, L., Yue, F., Zheng, Y., Russell, R., Serum zonulin is elevated in women with polycystic ovary syndrome and correlates with insulin resistance and severity of anovulation. Eur J Endocrinol 172 (2015), 29–36.
23. [23] Liu, Z.H., Huang, M.J., Zhang, X.W., Wang, L., Huang, N.Q., Peng, H., et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. Am J Clin Nutr 97 (2013), 117–126.
24. [24] The Oxford Centre for Diabetes, Endocrinology & metabolism. Diabetes trial unit. HOMA calculator. Available from: http://www.dtu.ox.ac.uk/ [Accessed April 2016].
25. [25] Katz, A., Nambi, S.S., Mather, K., Baron, A.D., Follmann, D.A., Sullivan, G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000), 2402–2410.
26. [26] Soininen, P., Kangas, A.J., Würtz, P., Suna, T., Ala-Korpela, M., Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet 8 (2015), 192–206.
27. [27] Basu, S., Haghiac, M., Surace, P., Challier, J.C., Guerre-Millo, M., Singh, K., et al. Pregravid obesity associates with increased maternal endotoxemia and metabolic inflammation. Obesity (Silver Spring) 19 (2011), 476–482, 10.1038/oby.2010.215 [Epub 2010 Oct 7].
28. [28] Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O. III, Criqui, M., et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003), 499–511.
29. [29] Ridker, P.M., Cardiology patient page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 108 (2003), e81–e85.
30. [30] Robbins, G.R., Wen, H., Ting, J.P., Inflammasomes and metabolic disorders: old genes in modern diseases. Mol Cell 54 (2014), 297–308.
31. [31] Alvarez, J.J., Montelongo, A., Iglesias, A., Lasunción, M.A., Herrera, E., Longitudinal study on lipoprotein profile, high density lipoprotein subclass, and postheparin lipases during gestation in women. J Lipid Res 37 (1996), 299–308.
32. [32] Kallio, K.A., Hätönen, K.A., Lehto, M., Salomaa, V., Männistö, S., Pussinen, P.J., Endotoxemia, nutrition, and cardiometabolic disorders. Acta Diabetol 52 (2015), 395–404.
33. [33] Hersoug, L.G., Møller, P., Loft, S., Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes Rev 17 (2016), 297–312.
34. [34] Muccioli, G.G., Naslain, D., Bäckhed, F., Reigstad, C.S., Lambert, D.M., Delzenne, N.M., et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol, 6, 2010, 392, 10.1038/msb.2010.46.
35. [35] Ozgu-Erdinc, A.S., Yilmaz, S., Yeral, M.I., Seckin, K.D., Erkaya, S., Danisman, A.N., Prediction of gestational diabetes mellitus in the first trimester: comparison of C-reactive protein, fasting plasma glucose, insulin and insulin sensitivity indices. J Matern Fetal Neonatal Med 28 (2015), 1957–1962.
36. [36] Maged, A.M., Moety, G.A., Mostafa, W.A., Hamed, D.A., Comparative study between different biomarkers for early prediction of gestational diabetes mellitus. J Matern Fetal Neonatal Med 27 (2014), 1108–1112.
37. [37] Salmi, A.A., Zaki, N.M., Zakaria, R., Nor Aliza, A.G., Rasool, A.H., Arterial stiffness, inflammatory and pro-atherogenic markers in gestational diabetes mellitus. Vasa 41:2 (2012), 96–104.
38. [38] Pöyhönen-Alho, M., Ebeling, P., Saarinen, A., Kaaja, R., Decreased variation of inflammatory markers in gestational diabetes. Diabetes Metab Res Rev 27 (2011), 269–276.
39. [39] Kim, S.Y., Sy, V., Araki, T., Babushkin, N., Huang, D., Tan, D., et al. Total adiponectin, but not inflammatory markers C-reactive protein, tumor necrosis factor-α, interluekin-6 and monocyte chemoattractant protein-1, correlates with increasing glucose intolerance in pregnant Chinese-Americans. J Diabetes 6 (2014), 360–368.
40. [40] Syngelaki, A., Visser, G.H., Krithinakis, K., Wright, A., Nicolaides, K.H., First trimester screening for gestational diabetes mellitus by maternal factors and markers of inflammation. Metabolism 65 (2016), 131–137.
41. [41] Retnakaran, R., Hanley, A.J., Raif, N., Connelly, P.W., Sermer, M., Zinman, B., C-reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metabol 88 (2003), 3507–3512.
42. [42] Ritchie, S.C., Würtz, P., Nath, A.P., Abraham, G., Havulinna, A.S., Fearnley, L.G., et al. The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection. Cell Syst 1 (2015), 293–301.
43. [43] Akinkuolie, A.O., Pradhan, A.D., Ridker, P.M., Mora, S., Novel protein glycan derived biomarker is associated with incident diabetes. Circulation, 2013, A18807.
44. [44] Akinkuolie, A.O., Buring, J.E., Ridker, P.M., Mora, S., A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc, 3, 2014, e001221, 10.1161/JAHA.114.001221.
45. [45] Connelly, M.A., Gruppen, E.G., Wolak-Dinsmore, J., Matyus, S.P., Riphagen, I.J., Shalaurova, I., et al. GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study. Clin Chim Acta 452 (2016), 10–17.
46. [46] Larsson, A., Palm, M., Hansson, L.O., Basu, S., Axelsson, O., Reference values for alpha1-acid glycoprotein, alpha1-antitrypsin, albumin, haptoglobin, C-reactive protein, IgA, IgG and IgM during pregnancy. Acta Obstet Gynecol Scand 87 (2008), 1084–1088.
47. [47] Ruhaak, L.R., Uh, H.W., Deelder, A.M., Dolhain, R.E., Wuhrer, M., Total plasma N-glycome changes during pregnancy. J Proteome Res 13 (2014), 1657–1668.
48. [48] Chu, C.Y., Singla, V.P., Wang, H.P., Sweet, B., Lai, L.T., Plasma alpha 1-acid glycoprotein levels in pregnancy. Clin Chim Acta 112 (1981), 235–240.
49. [49] Honda, M., Omori, Y., Minei, S., Oshiyama, T., Shimizu, M., Sanaka, M., et al. Quantitative analysis of serum alpha 1-acid glycoprotein levels in normal and diabetic pregnancy. Diabetes Res Clin Pract 10 (1990), 147–152.
50. [50] Yaghmaei, M., Hashemi, M., Shikhzadeh, A., Mokhtari, M., Niazi, A., Ghavami, S., Serum trypsin inhibitory capacity in normal pregnancy and gestational diabetes mellitus. Diabetes Res Clin Pract 84:3 (2009), 201–204, 10.1016/j.diabres.2009.03.003 [Epub 2009 Apr 2].